Literature DB >> 28780511

Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece.

Irini Gergianaki1,2, Antonis Fanouriakis3, Argyro Repa1, Michalis Tzanakakis1, Christina Adamichou1, Alexandra Pompieri1, Giorgis Spirou1, Antonios Bertsias4, Eleni Kabouraki1, Ioannis Tzanakis5, Leda Chatzi4,6,7, Prodromos Sidiropoulos1,2, Dimitrios T Boumpas2,3,8,9,10, George K Bertsias1,2.   

Abstract

OBJECTIVES: Several population-based studies on systemic lupus erythematosus (SLE) have been reported, yet community-based, individual-case validated, comprehensive reports are missing. We studied the SLE epidemiology and burden on the island of Crete during 1999-2013.
METHODS: Multisource case-finding included patients ≥15 years old. Cases were ascertained by the ACR 1997, SLICC 2012 criteria and rheumatologist diagnosis, and validated through synthesis of medical charts, administrative and patient-generated data.
RESULTS: Overall age-adjusted/sex-adjusted incidence was 7.4 (95% CI 6.8 to 7.9) per 100 000 persons/year, with stabilising trends in women but increasing in men, and average (±SD) age of diagnosis at 43 (±15) years. Adjusted and crude prevalence (December 2013) was 123.4 (113.9 to 132.9) and 143 (133 to 154)/105 (165/105 in urban vs 123/105 in rural regions, p<0.001), respectively. Age-adjusted/sex-adjusted nephritis incidence was 0.6 (0.4 to 0.8) with stable trends, whereas that of neuropsychiatric SLE was 0.5 (0.4 to 0.7) per 100 000 persons/year and increasing. Although half of prevalent cases had mild manifestations, 30.5% developed organ damage after 7.2 (±6.6) years of disease duration, with the neuropsychiatric domain most frequently afflicted, and 4.4% of patients with nephritis developed end-stage renal disease. The ACR 1997 and SLICC 2012 classification criteria showed high concordance (87%), yet physician-based diagnosis occurred earlier than criteria-based in about 20% of cases.
CONCLUSIONS: By the use of a comprehensive methodology, we describe the full spectrum of SLE from the community to tertiary care, with almost half of the cases having mild disease, yet with significant damage accrual. SLE is not rare, affects predominantly middle-aged women and is increasingly recognised in men. Neuropsychiatric disease is an emerging frontier in lupus prevention and care. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  epidemiology; incidence; lupus nephritis; neuropsychiatric lupus; prevalence

Mesh:

Year:  2017        PMID: 28780511     DOI: 10.1136/annrheumdis-2017-211206

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

Review 1.  Epidemiology of systemic lupus erythematosus: an update.

Authors:  George Stojan; Michelle Petri
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

Review 2.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

Review 3.  RNA Methylation in Systemic Lupus Erythematosus.

Authors:  Xinyi Lv; Xiaomin Liu; Ming Zhao; Haijing Wu; Wuiguang Zhang; Qianjin Lu; Xiangmei Chen
Journal:  Front Cell Dev Biol       Date:  2021-07-07

4.  Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease.

Authors:  Dionysis S Nikolopoulos; Myrto Kostopoulou; Dimitrios T Boumpas; Antonis Fanouriakis; Antigoni Pieta; Sofia Flouda; Katerina Chavatza; Aggelos Banos; John Boletis; Pelagia Katsimbri
Journal:  Lupus Sci Med       Date:  2020-06

5.  Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity.

Authors:  Nikolaos I Panousis; George K Bertsias; Halit Ongen; Irini Gergianaki; Maria G Tektonidou; Maria Trachana; Luciana Romano-Palumbo; Deborah Bielser; Cedric Howald; Cristina Pamfil; Antonis Fanouriakis; Despoina Kosmara; Argyro Repa; Prodromos Sidiropoulos; Emmanouil T Dermitzakis; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2019-06-05       Impact factor: 19.103

6.  Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov.

Authors:  Yanfang Gao; Yuhan Wang; Rongshan Li; Xiaoshuang Zhou
Journal:  Front Med (Lausanne)       Date:  2021-06-17

Review 7.  Global epidemiology of systemic lupus erythematosus.

Authors:  Megan R W Barber; Cristina Drenkard; Titilola Falasinnu; Alberta Hoi; Anselm Mak; Nien Yee Kow; Elisabet Svenungsson; Jonna Peterson; Ann E Clarke; Rosalind Ramsey-Goldman
Journal:  Nat Rev Rheumatol       Date:  2021-08-03       Impact factor: 32.286

Review 8.  Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.

Authors:  Irini Gergianaki; George Bertsias
Journal:  Front Med (Lausanne)       Date:  2018-05-29

9.  Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study.

Authors:  Rosalie Magro; Andrew A Borg
Journal:  Biomed Res Int       Date:  2018-09-30       Impact factor: 3.411

10.  Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus.

Authors:  Christina Adamichou; Dionysios Nikolopoulos; Emmanouil Papastefanakis; Eleni Kalogiannaki; Irini Gergianaki; Aggeliki Kountouri; Argyro Repa; Nestor Avgoustidis; Nikolaos Kougkas; Prodromos Sidiropoulos; Antonis Fanouriakis; George Bertsias
Journal:  Mediterr J Rheumatol       Date:  2018-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.